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We recently identiﬁed ASP5736, (N-(diaminomethylene)-1-(3,5-diﬂuoropyridin-4-yl)-4-ﬂuoroi-
soquinoline-7-carboxamide (2E)-but-2-enedioate), a novel antagonist of 5-HT5A receptor, and
here describe the in vitro and in vivo characterization of this compound. ASP5736 exhibited
a high afﬁnity for the human 5-HT5A receptor (Ki=3.670.66 nM) and antagonized 5-
carboxamidotryptamine (5-CT)-induced Ca2+ inﬂux in human cells stably expressing the
5-HT5A receptor with approximately 200-fold selectivity over other receptors, including other
5-HT receptor subtypes, enzymes, and channels except human 5-HT2c receptor (Ki=286.8 nM)
and 5-HT7 receptor (Ki=122.9 nM). Further, ASP5736 dose-dependently antagonized the 5-CT-
induced decrease in cAMP levels in HEK293 cells stably expressing the 5-HT5A receptor. We then
evaluated the effects of ASP5736 on cognitive impairments in several animal models of
schizophrenia. Working memory deﬁcit in MK-801-treated mice and visual learning deﬁcit in
neonatally phencyclidine (PCP)-treated mice were both ameliorated by ASP5736. In addition,
ASP5736 also attenuated MK-801- and methamphetamine (MAP)-induced hyperactivity in mice
without causing sedation, catalepsy, or plasma prolactin increase. The addition of olanzapine
did not affect ASP5736-induced cognitive enhancement, and neither the sedative nor
cataleptogenic effects of olanzapine were worsened by ASP5736. These results collectively
suggest that ASP5736 is a novel and potent 5-HT5A receptor antagonist that not only ameliorates
positive-like symptoms but also cognitive impairments in animal models of schizophrenia,o.2014.07.009
CNP.
863 7156; fax: +81 29 856 2515.
astellas.com (M. Yamazaki).
Open access under CC BY-NC-ND license.
1699ASP5736, a novel 5-HT5A receptor antagonistwithout adverse effects. Present studies also indicate that ASP5736 holds potential to satisfy
currently unmet medical needs for the treatment of schizophrenia by either mono-therapy or
co-administered with commercially available antipsychotics.
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Figure 1 Chemical structure of ASP5736. N-(diaminomethy-
lene)-1-(3,5-diﬂuoropyridin-4-yl)-4-ﬂuoroisoquinoline-7-car-
boxamide (2E)-but-2-enedioate.1. Introduction
Schizophrenia is a chronic, severe, and disabling psychiatric
disease involving three major symptom classes (positive,
negative, and cognitive). Cognitive impairments of schizo-
phrenia have been increasingly focused because the cogni-
tive impairments are known to be better predictors of
functional outcome than indices from any other symptom
domain such as positive symptom or negative symptom.
(Green MF 1996, Hofer A et.al. 2005) However, no available
antipsychotic has shown the clinically beneﬁcial efﬁcacy for
the impairments. (Hill SK 2010)
Add-on pharmacological agents have been posited as
potentially useful in relieving these as-yet untreated symp-
toms, as they can be used to modulate speciﬁc neurotrans-
mitter systems hypothesized to be involved in cognitive
functions. In the last decade, evidence has emerged that
many cognitive domains are affected in schizophrenia,
including attention, executive function, working memory,
and visual and verbal learning and memory. Improvements
in neurocognitive deﬁcits have also been reported to be
better predictors of social function than improvements in
psychotic symptoms (Green, 2006).
The 5-HT5A receptor is a G-protein-coupled seven-trans-
membrane receptor and the human gene of this receptor
was cloned in 1994 (Rees et al., 1994). However, few reports
have touched on the function of the receptor due to a lack
of speciﬁc ligands. Findings from 5-HT5A receptor mRNA
localization (Rees et al., 1994, Pasqualetti et al., 1998)
and immunolabelling studies (Oliver and Kinsey, 2000)
have revealed widespread expression of this receptor in
the central nervous system, including the cerebral cortex,
hippocampus, nucleus accumbens, amygdala, and hypo-
thalamus. In a number of these brain areas, the 5-HT5A
receptor is expressed on neurons (e.g. on rat cortical
and hippocampal pyramidal neurons) with little expression
in peripheral tissues, which has provided insight into the
potential roles of the receptor. In addition, increased
exploratory behavior in novel environments displayed by
5-HT5A receptor KO mice compared to wild-type mice
(Grailhe et al., 2001), together with the widespread loca-
lization pattern, has suggested that the 5-HT5A receptor is
involved in mood, affective disorder, and cognitive function,
while gene association studies imply that the 5-HT5A recep-
tor may also play a role in schizophrenia and mood distur-
bance (Thomas, 2006, Jongen-Relo et al., 2006, Rueter
et al., 2006).
ASP5736 (N-(diaminomethylene)-1-(3,5-diﬂuoropyridin-4-
yl)-4-ﬂuoroisoquinoline-7-carboxamide (2E)-but-2-enedio-
ate) (Figure 1) is a novel, potent and selective 5-HT5A
receptor antagonist originally synthesized by Astellas
Pharma Inc. Here, we evaluated the in vitro inhibitory
effects of this compound on the 5-HT5A receptor, its afﬁnityfor various receptors, and its pharmacokinetics. We also
evaluated the compound in animal models of positive-like
symptoms, and cognitive impairment of schizophrenia. The
efﬁcacy and safety of ASP5736 was also tested in animal
models in combination with an existing anti-psychotic,
olanzapine, to determine if the drug can be used in com-
bination with existing medicines.
2. Experimental procedures
2.1. Drugs and treatment
ASP5736, and phencyclidine hydrochloride (used as PCP) were
synthesized at Astellas Pharma Inc. (Tsukuba, Japan). Olanzapine
(brand name: Zyprexa) was purchased from Eli Lilly (Indianapolis,
USA) and extracted at Astellas Pharma Inc. Methamphetamine
hydrochloride (MAP) and (+)–MK-801 hydrogen maleate (MK-801)
were purchased from Dainippon Sumitomo Pharma Co., Ltd. (Tokyo,
Japan) and Sigma Aldrich (St. Louis, MO, USA), respectively.
ASP5736 and olanzapine were suspended in 0.5% (w/v) methyl
cellulose (MC) and PCP, MAP, and MK-801 in saline. All compounds
were administered at 10 mL/kg in mice and 1 mL/kg in rats.
ASP5736 was corrected for salt content.
2.2. Inhibition of 5-HT5A receptor
2.2.1. Afﬁnity of ASP5736 for human and mouse 5-HT5A
receptor
2.2.1.1. Acquisition of HEK293 cells stably expressing human 5-
HT5A receptor. An open reading frame (ORF) of the human 5-HT5A
receptor (GenBank AF498985) was ﬁrst cloned from a human whole
brain cDNA library and then inserted into a pCR2.1 vector (Life
Technologies, Carlsbad, CA, USA), and Escherichia coli containing
the plasmid was mass cultured. The human 5-HT5A receptor full-
length cDNA sequence was then analyzed, inserted into a pCDNA3.1
recombinant expression vector (Life Technologies), and its plasmid
was mass cultured. Human embryonic kidney-induced (HEK) 293
cells (American Type Culture Collection, Manassas, VA, USA) were
seeded, and the aforementioned expression plasmid (1 mg) was
added in combination with lipofectamine 2000 (Life Technologies;
2 mL), to introduce the gene. Geneticin (G418 sulfate 500 mg/mL;
M. Yamazaki et al.1700Kanto Chemical Co., Inc., Tokyo, Japan) was used as a drug-
resistant marker to screen cells for cells expressing the human 5-
HT5A receptor.
2.2.1.2. Inhibition of human 5-HT5A receptor binding to test
compounds. Cell membranes (25 μg of protein), [3H]5-CT (5-car-
boxamidotryptamine) (1.5 nM at ﬁnal concentration), and test
compounds (0.03–30 μM at ﬁnal concentration) were placed in 96-
well plates and incubated for 60 min at 37 1C in incubation buffer
(Tris(HCl) pH7.4 50 mM, MgSO4 10 mM, EDTA 0.5 mM). The reaction
was terminated via rapid ﬁltration through 96-well GF/C ﬁlter
plates (PerkinElmer Inc.) pre-soaked in 0.3% polyethyleneimine for
30 min. Filter plates were washed 5 times with 50 mM Tris HCl at
pH 7.4 and dried. Liquid scintillant (30 mL; MicroScintTM-20, Perki-
nElmer Inc., Waltham, MA, USA) was placed on the ﬁlters, and the
radioactivity was measured using a TopCount (PerkinElmer Inc.).
Nonspeciﬁc binding was determined with 1.5 μM 5-CT.
Values of the apparent equilibrium dissociation constant of
inhibitors (Ki) were calculated using SAS version 8.2 (SAS Institute
Inc., Cary, NC, USA). Mean and standard error of the mean (SEM)
were obtained from three independent experiments. To test the
inhibitory effect following the binding of [3H]5-CT to the compound
in each experiment, the IC50 value was calculated by measuring
radioactivity when only DMSO was added as (0% inhibition), and
when 1.5 mM 5-CT was added (100% inhibition). All other Ki values
were calculated using the following equation:
K i ¼ IC50=ð1þConcentration of the ligands added=KdÞ
The Kd value of [3H]5-CT was determined with non-linear regres-
sion analysis.
2.2.2. Antagonistic effect of ASP5736 on human 5-HT5A
receptor
We established HEK293 cells that stably expressed the human 5-
HT5A receptor and G15α, and examined the effect of ASP5736 on 5-
CT-induced Ca inﬂux using a ﬂuorescence imaging plate reader
(FLIPR) (Molecular Devices, Sunnyvale, CA, USA) (Noda et al. 2003).
HEK293 cells harvested on a 384-well plate were incubated with
assay buffer (1 Hank's balanced salt solution (Life Technologies),
20 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES)
(Sigma-Aldrich)) containing 1 μM 1-[2-amino-5-(2,7-diﬂuoro-6-acetoxy-
methoxy-3-oxo-9-xanthenyl)phenoxy]-2-(2-amino-5-methylphenoxy)
ethane-N,N,N0,N0-tetraacetic acid, tetra(acetoxymethyl) ester (Fluo
4-AM) (Dojindo, Kumamoto, Japan), 0.01% F-127 pluronic acid (Life
Technologies), and 625 μM probenecid (Sigma-Aldrich) for 1.5 h.
ASP5736 (0.0125–1250 nM) dissolved in assay buffer containing 0.02%
CHAPS (Nacalai Tesque, Inc., Kyoto, Japan) was applied for 15 min, and
then 62.5 nM 5-CT was applied. Ca inﬂux was monitored with FLIPRtetra,
and differences were analyzed using ScreenWorks™ software (Molecular
Devices).
2.3. Antagonistic effect of ASP5736 on 5-CT-induced
decrease in cAMP levels in cells stably expressing human
5-HT5A receptor
Intracellular cAMP content was measured with GloSensor™ cAMP
Assay (Promega, Fitchburg, WI, USA). Native or 5-HT5A-expressing
HEK293 cells were transfected with GloSensorTM plasmid using
Lipofectamine 2000 (Life Technologies) in Opti-MEM (Life Technol-
ogies). After 24 h, cells were incubated in assay buffer (1 HBSS
and 20 mM HEPES) containing 2% luciferin (Promega) at 37 1C for 1 h
and room temperature for 1 h. ASP5736 and 1 μM forskolin (Wako
Pure Chemical Industries, Ltd., Osaka, Japan) were treated in
the presence of 50 nM SB269970, a selective 5-HT7 antagonist
(Hagan et.al, 2000, Peter et al., 2000), for 15 min. 5-CT (30 nM)
was applied for 30 min, and luminescence was monitored usingFLIPRtetra in luminescence mode. Area under the curve (AUC) was
calculated using ScreenWorks™ software (Molecular Devices).
2.4. Afﬁnity for multiple receptors, ion channels and
transporters
To determine the afﬁnity of ASP5736 for a wide range of receptors,
transporters and ion channels, initial receptor binding screens (62
assays) were conducted with duplicate samples of 1 μM ASP5736 by
Sekisui Medical Inc. (Tokyo, Japan) using proprietary assay formats.
2.5. Animals
Mice were housed in groups of 10 in temperature- and humidity-
controlled rooms (2371 1C and 5575%) under a 12-h light-dark
cycle with water and laboratory chow available ad libitum. All
animals were experimentally naive and used only once. All in vivo
experimental procedures were performed under lit conditions. All
animal experimental procedures were approved by the Institutional
Animal Care and Use Committee of Astellas Pharma Inc. Further, the
Astellas Pharma Inc. Tsukuba Research Center was awarded Accred-
itation Status by the AAALAC International. All efforts were made to
minimize the number of animals used and to avoid suffering and
distress.
2.6. Pharmacokinetic study in mice
Experiments were performed using ﬁve-week-old male ddY mice
(Japan SLC, Inc., Hamamatsu, Japan), which had been freely
feeding. In the ﬁrst examination, animals received an oral (p.o.)
administration of ASP5736 (0.03 mg/kg) (suspended in 0.5% MC) and
were kept in rearing cages. Under isoﬂurane anesthesia, the
animals were sacriﬁced, and whole blood samples were taken using
a syringe containing heparin sodium at 0.5, 1, and 2 h post-dose.
Given that a above experiment revealed the Tmax of this compound
to be 1 h, animals received an oral administration of ASP5736
(0.01 mg/kg) and were sacriﬁced under isoﬂurane anesthesia at 1 h
post-dose, and whole blood samples were taken using a syringe
containing heparin sodium. After collection of whole blood, the
cerebrum was also removed from each animal. Whole blood samples
were centrifuged to separate plasma. Plasma and cerebrum were
stored at 20 1C until assay.
For the analysis, 25 μL plasma was mixed with 25 μL 50%
acetonitrile and 200 μL acetonitrile containing internal standard
(IS; ﬁnal: 20 ng/mL diazepam). The mixture was subjected to
centrifugation at 2150g for 10 min, and the resulting supernatant
was injected into a LC-MS/MS system. This consisted of the
Prominence HPLC system (Shimadzu, Kyoto, Japan) with an XTerra
MS C18 column (4.6 50 mm2, 5 μm particle size, Waters, Milford,
MA, USA) and an API4000 LC/MS/MS instrument (AB SCIEX, Framing-
ham, MA, USA). Data were processed using Analyst software (AB
SCIEX, Ontario, Canada), and the concentration of ASP5736 was
calculated via an internal standard.
2.7. Animal models of schizophrenia
2.7.1. MK-801-induced working memory deﬁcit in mice during
Y-maze test
Spatial working memory performance was assessed by recording
spontaneous alternation behavior of male ddY mice (aged 5-6
weeks, Japan SLC, Inc.) in a Y-maze as previously described
(Maurice and Privat, 1997). The maze was constructed from gray
polyvinyl chloride, with arms (length, 40 cm; height, 13 cm; width
at bottom, 3 cm; and width at top, 10 cm) converging at equal
angles. Thirty minutes after p.o. administration of ASP5736,
olanzapine, or vehicle, 0.15 mg/kg of MK-801 was administered
1701ASP5736, a novel 5-HT5A receptor antagonistintraperitoneally (i.p.) to each animal. Control animals were
administered vehicle instead of ASP5736 and saline instead of
MK-801 (i.p.). Twenty minutes after administration of MK-801 or
saline, each mouse was placed at the end of one arm and allowed to
freely explore the apparatus for 8 min. The total number of arm
entries was recorded for each animal throughout the period.
Alternation was deﬁned as entries into all three arms on consecu-
tive occasions. The alternation rate was calculated using the
following formula:
Alternation rate ð%Þ ¼ 100 Number of alternations=
ðNumber of total arm entries2Þ
2.7.2. Novel object recognition test (NORT) in neonatally PCP-
treated mice
Three-day-old male ddY mice (Japan SLC, Inc.) were housed 10–12
per cage with a stepmother. Saline or PCP (15 mg/kg) was adminis-
tered subcutaneously once daily on days 7, 9, and 11 after birth.
The mice were separated from their mother at 3 weeks of age, and
used for NORT at 8–9 weeks old. Neonatal mice were treated with
PCP, and the NORT was conducted as previously described (Harada
et al., 2012).
The NORT consists of three different sessions: habituation,
training, and testing. Each mouse was individually habituated to
the box for 5 min in the absence of objects (habituation session).
After 3–4 h, two different objects (objects A and B) were placed
symmetrically 10 cm away from the two opposite corners of the
back wall. The objects A and B were always in the same location.
The animal was placed into the box facing a side-wall and allowed
to explore the box for 5 min (training session). ASP5736 and
olanzapine were orally administered about 60 and 50 min before
the training session, respectively. Control animals were adminis-
tered with vehicle instead of ASP5736. After the training session,
the mouse was placed back in its home cage. After a 24 h retention
interval, the object B was replaced with a novel object (object C.)
The animal was placed back into the same box now with one
familiar object (object A) and one novel object (object C), and
allowed to explore the box for 5 min (testing session). The time
spent exploring each object during the training and testing sessions
was recorded. Exploration was deﬁned as inquisitive activity
directed toward the object, such as touching it with the nose or
limbs, or snifﬁng the object. Exploratory preference was deter-
mined to assess cognitive function using the following formula:
Exploratorypreference ð%Þ
¼ 100  ðTimes pent exploring novel objectÞ=
ðTotal time exploring both objectsÞ
The researcher was blind to the treatment condition of mice.
2.7.3. Spontaneous activity in mice
Five-week-old male ICR mice administered ASP5736, olanzapine, or
vehicle (p.o.) were placed individually in experimental cages
(LWH: 30 35 17.5 cm3), and their locomotor activity wasTable 1 In vitro 5-HT5A receptor binding afﬁnity and 5-CT-indu
IC50 (nM) Ki
Human 5-HT5A receptor 4.670.82 3.6
5-CT-induced Ca inﬂux 1.070.09 –
Data represent mean7SEM of three independent experiments.recorded for 60 min via SUPERMEX (Muromachi Kikai Co. Ltd.,
Tokyo, Japan).2.7.4. MAP-induced hyperactivity in mice
Five-week-old male ICR mice administered ASP5736, olanzapine, or
vehicle (p.o.) were individually placed into experimental cages
(LWH: 30 35 17.5 cm3). After 30 min, each mouse received
a subcutaneous (s.c.) administration of MAP (1.5 mg/kg), were
individually replaced into experimental cages, and their locomotor
activity was recorded for 60 min via SUPERMEX (Muromachi Kikai
Co. Ltd.).2.7.5. Catalepsy in mice
Five-week-old male ICR mice were administered ASP5736, olanza-
pine, or vehicle (p.o.). After 60 min, each mouse was assessed for
catalepsy for 120 s. Catalepsy was measured via the bar method,
which consists of placing an animal following drug administration,
with its front legs resting on a bar suspended above the ﬂoor of the
test apparatus. Intensity of catalepsy was measured as the length of
time the test subject maintains this abnormal posture. Catalepsy
time (duration of catalepsy) was calculated.2.7.6. Plasma prolactin concentration in mice
Experiments were performed using nine-week-old male ICR mice
(Japan SLC, Inc., Hamamatsu, Japan) which had been freely
feeding. ASP5736 and risperidone (0.1 mg/kg) were orally adminis-
tered (by 0.5% MC), and mice were kept in rearing cages. Under
isoﬂurane anesthesia, animals were sacriﬁced, and whole blood
samples were taken using a syringe containing heparin sodium at
1 or 0.5 h post-dose, respectively. Whole blood samples were
centrifuged to separate plasma. Plasma was stored at 20 1C until
assay. Plasma prolactin levels were measured using an enzyme-
linked immunosorbent assay (ELISA; Calbiotech, Spring Valley, CA,
USA) with a sensitivity of 0.2 ng/mL.2.8. Co-administration with olanzapine in animal
models of schizophrenia
2.8.1. Effect of ASP5736 and olanzapine on MK-801-induced
working memory deﬁcit in mice during Y-maze test
Methods were the same as in Section 2.7.1. MK-801 (0.15 mg/kg,
i.p.) was administered to each animal 30 min after administration
of ASP5736 or vehicle with olanzapine (1 mg/kg, p.o.).2.8.2. Effect of ASP5736 and olanzapine on spontaneous
activity in mice
Methods were the same as in Section 2.7.3. Olanzapine or vehicle
was administered in combination with ASP5736 (0.003 mg/kg, p.o.)
to 5-week-old male ICR mice that were then individually placed into
experimental cages with locomotor activity recorded for 60 min via
SUPERMEX.ced Ca inﬂux in 5-HT5A receptor
(nM) Reference
Compound IC50 (nM)
70.66 Methiothepin 3.370.52
Methiothepin 29007420
M. Yamazaki et al.17022.8.3. Effect of ASP5736 and olanzapine on MAP-induced
hyperactivity in mice
Methods were the same as in Section 2.7.4. Olanzapine or vehicle
was administered in combination with ASP5736 (0.003 mg/kg, p.o.)
to 5-week-old male ICR mice that were individually placed into
experimental cages with locomotor activity recorded for 60 min via
SUPERMEX.
2.8.4. Effect of ASP5736 on catalepsy in mice with olanzapine
Methods were the same as in Section 2.7.5. Olanzapine or vehicle
was administered to 5-week-old male ICR mice with ASP5736
(0.003 mg/kg, p.o.). After 60 min, each mouse was assessed for
catalepsy for 120 sec.
2.9. Statistical analysis
All values are expressed as mean7standard error of the mean
(SEM). Values for IC50 were determined by ﬁtting the data to a
logistic equation using SAS software (SAS Institute Inc., Cary, NC,Table 2 Plasma and brain concentration of ASP5736 in mice
ASP5736 0.01 mg/kg, p.o.
Plasma (ng/mL) Brain (ng/g) Kp bra
0.5 h – – –
1 h 5.671.0 0.570.1 0.08
2 h – – –
Data expressed as mean7SEM of duplicate samples (n=3).
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Figure 2 Intracellular cAMP concentration in cells stably
expressing 5-HT5A receptor. cAMP levels were decreased by
5-CT (30 nM), a non-selective 5-HT5A agonist, in cells stably
expressing 5-HT5A receptors. ASP5736 dose-dependently antag-
onized this decrease. In contrast, in native cell, cAMP didn't
change by 5-CT or ASP5736. All data are mean7SEM (n=4 for
each time point). ##Po0.01, statistically signiﬁcant compared
with vehicle-treated forskolin (1 μM) group (Student's t-test).
**Po0.01, statistically signiﬁcant compared with vehicle-trea-
ted 5-CT group (Dunnett's multiple comparison test).USA). Student's t-test was used for statistical analysis of control
(vehicle- and saline-treated) group vs. vehicle- and MAP-treated
group, vehicle- and MK-801-treated group and vehicle- and PCP-
treated group. Dunnett's multiple comparison test was used to
compare multiple groups. For all tests, Po0.05 was considered
signiﬁcant.
3. Results
3.1. Binding to 5-HT5A receptor and blocking of
function
ASP5736 bound to the human 5-HT5A receptor with a Ki
value of 3.770.66 nM. ASP5736 inhibited 5-CT-induced Ca2+
inﬂux using cells stably expressing both 5-HT5A receptor
and G15α (as determined using 5-HT5A receptor functional
screening of compounds) with an IC50 value of 1.070.09 nM.
Ki and IC50 values for ASP5736 are summarized in Table 1.
Further, ASP5736 antagonized the 5-CT-induced decrease in
cAMP in cells stably expressing the human 5-HT5A receptor
in a dose-dependent manner (Figure 2).
3.2. Plasma and brain concentration studies in
mice
ASP5736 concentration was observed in plasma and whole
brain in mice at 0.5, 1, and 2 h following oral administration
of the compound (0.03 mg/kg) as shown in Table 2, suggest-
ing that ASP5736 is orally absorbable and CNS penetrable.
As the Tmax of ASP5736 (0.03 mg/kg, p.o.) in the brain
ranged from 1 to 2 h, we adopted a 60-min post-adminis-
tration period for subsequent pharmacology studies.
Further, brain concentrations with 0.01 and 0.03 mg/kg
were nearly dose-proportional.
3.3. Afﬁnity for multiple receptors, ion channels
and transporters
The afﬁnity of ASP5736 for 54 receptors, 7 ion channels, and
4 transporters was evaluated using a radioligand binding
panel screen. At a concentration of 1 mM, ASP5736 did not
inhibit ligand binding to any target by more than 50%,
except for human 5-HT2c receptor and 5-HT7 receptors
(Table S-1). Subsequent concentration-response experi-
ments showed that ASP5736 inhibited [3H]-5-HT binding to
human 5-HT2c receptor and 5-HT7 receptors with Ki value of
286.8 nM and 122.9 nM, respectively.0.03 mg/kg, p.o.
in Plasma (ng/mL) brain (ng/g) Kp brain
10.871.7 1.270.6 0.11
9.571.0 1.570.8 0.15
10.470.5 1.570.8 0.14
Figure 3 Effect of ASP5736 and olanzapine on MK-801-induced
working memory deﬁcit in mouse Y-maze test. (A) Effect of
ASP5736 alone. ##Po0.01, statistically signiﬁcant compared
with control (vehicle- and saline-treated) group (Student's
t-test). **Po0.01, statistically signiﬁcant compared with vehi-
cle-treated MK-801 group (Dunnett's multiple comparison test).
(B) Effect of olanzapine alone. ##Po0.01, statistically signiﬁ-
cant compared with control (vehicle- and saline-treated) group
(Student's t-test). (C) Effect of ASP5736 in combination with
olanzapine. The dose of olanzapine was determined from the
inhibition dose (ID50 value) of MAP induced-hyperactivity. C,
control (vehicle- and saline-treated); V, vehicle (vehicle- and
MK-801-treated); and 0, 0 mg/kg ASP5736 (olanzapine 1 mg/kg-
MK-801). ##Po0.01, statistically signiﬁcant compared with
control (vehicle- and saline-treated) group (Student's t-test).
**Po0.01, statistically signiﬁcant compared with olanzapine
1 mg/kg-treated MK-801 group (Dunnett's multiple comparison
test). Each value shows the mean7SEM (n=8 for each group).
Figure 4 Effect of ASP5736 and olanzapine on neonatal PCP
treatment-induced learning deﬁcit in mice during novel object
recognition test. Saline or PCP (15 mg/kg) was subcutaneously
administered at postnatal days 7, 9, and 11. Exploratory
preference for novel object in the testing session was mea-
sured. Effects of ASP5736 (A) and olanzapine (B) are shown.
Values shown represent mean7SEM. Number in parenthesis
indicates number of mice in each group. ##Po0.01, statistically
signiﬁcant compared with control neonatal saline group
(Student's t-test). *Po0.05, statistically signiﬁcant compared
with vehicle-treated neonatal PCP group (Dunnett's multiple
comparison test).
1703ASP5736, a novel 5-HT5A receptor antagonist3.4. Evaluation of ASP5736 in animal models
of schizophrenia
3.4.1. MK-801-induced working memory deﬁcit in
mouse Y-maze test
We examined the effect of ASP5736 on working memory
disruption in mice based on observation of spontaneous
alternation behavior in a Y-maze with MK-801. We also
evaluated the effect of this compound in combination with
olanzapine on spontaneous alternation behavior. Adminis-
tration of MK-801 consistently induced a marked decrease in
the alternation rate in the Y-maze test in each experiment
(Po0.001, by Student's t-test), as coinciding with previous
results (Parada-Turska and Turski, 1990). ASP5736 signiﬁ-
cantly attenuated the MK-801-induced decrease in alterna-
tion rate, and statistical analysis revealed that the effect of
Figure 5 Effect of ASP5736 and olanzapine on spontaneous
activity in mice. (A) Effect of ASP5736 alone. ASP5736 did not
affect spontaneous activity at any doses. (B) Effect of olanza-
pine alone. **Po0.01, statistically signiﬁcant compared with
vehicle-treated group (Dunnett's multiple comparison test).
(C) Effect of olanzapine in combination with ASP5736. We
determined the dose of ASP5736 from the effective dose of
MK-801-Y-maze and nPCP-NORT study. Control, vehicle-treated,
OLZ, olanzapine and ASP, ASP5736 0.003 mg/kg-treated.
**Po0.01, statistically signiﬁcant compared with ASP (vehicle-
and ASP5736 0.003 mg/kg-treated ) group (Dunnett's multiple
comparison test). Each value represents mean7SEM (n=8 for
each group).
M. Yamazaki et al.1704ASP5736 was signiﬁcant at doses of 0.001 and 0.003 mg/kg
(p.o.) (Figure 3A).
We then evaluated the effect of ASP5736 on spontaneous
alternation behavior in combination with olanzapine at 1 mg/kg
(p.o.), which was the dose selected based on the potencyof inhibitory effect on MAP-induced hyperlocomotion in our
preliminary study. Olanzapine alone had no effect on MK-801-
induced spontaneous alternation behavior deﬁcit (Figure 3B).
However, ASP5736 in combination with olanzapine still signiﬁ-
cantly attenuated the spontaneous alternation behavior deﬁcit
as the same degree as ASP5736 alone (Figure 3C).
Furthermore, we also evaluated the effect of ASP5736 on
spontaneous alternation behavior in treatment (MK-801)-
free mice in separate experiments. The compound did not
affect the alternation rate (Table S-3).
3.4.2. Neonatal PCP treatment-induced learning deﬁcit
in mouse NORT
The NORT task is a model for assessing visual-recognition
memory which takes thadvantage of the natural preference
of mice for novelty (mice that recognize a familiar object
will instinctively spend more time exploring novel objects)
(Ennaceur and Delacour, 1988). Neonatal PCP treatment
impairs the ability to perform this task in adults (Harada K.
et al., 2012). Here, we evaluated the effect of ASP5736 on
neonatal PCP-induced deﬁcits in mice. No particular pre-
ference was noted for either of two objects presented in
the training session (data not shown). However, while
control mice (treated neonatally with saline) spent nearly
70% of total time exploring the novel object in the test
session, mice treated neonatally with PCP spent approxi-
mately only 50% of total time exploring the novel object, a
signiﬁcant difference compared with control mice (Po0.01,
by Student's t-test) (Figure 4A and B). This ﬁnding suggests
that neonatal PCP treatment did indeed impair the cogni-
tion of mice in the NORT. ASP5736 increased the exploratory
preference in neonatally PCP-treated mice and signi-
ﬁcantly improved memory impairment at 0.003 mg/kg
(p.o.) (Figure 4A). In contrast, olanzapine did not change
the exploratory preference in neonatally PCP-treated mice
(Figure 4B).
3.4.3. Effect of ASP5736 on spontaneous locomotor
activity in mice
Antipsychotic drugs are known to decrease spontaneous activ-
ity. In the present study, olanzapine decreased spontaneous
activity in a dose-dependent manner in mice (Figure 5B). We
examined the effect of ASP5736 on spontaneous activity in
mice, and also evaluated the effects of this compound in
combination with olanzapine on spontaneous activity. As shown
in Figure 5A, ASP5736 exerted no decrease in spontaneous
activity from 0.01 to 100 mg/kg (p.o.) in mice. Further, the
inhibitory effect of olanzapine on spontaneous activity was not
enhanced by ASP5736 at 0.003 mg/kg (Figure 5C), the dose at
which MK-801-induced spontaneous alternation deﬁcit was
ameliorated.
3.4.4. Effect of ASP5736 on MAP-induced hyperactivity
in mice
Figure 6A and B show the effects of ASP5736 and olanzapine on
MAP-induced hyperactivity in mice, respectively. MAP-treated
mice showed signiﬁcant hyperactivity compared with control
(vehicle-saline treated) mice, as shown in Figure 6 (Po0.001,
by Student's t-test). Treatment with ASP5736 signiﬁcantly
reversed MAP-induced hyperactivity at the doses of 0.01–
0.1 mg/kg as shown in Figure 6A. In contrast, olanzapine
1705ASP5736, a novel 5-HT5A receptor antagonistsigniﬁcantly decreased this hyperactivity in a dose-dependent
manner as shown in Figure 6B (Po0.01; by Dunnett's multiple
comparison test). We also evaluated the combined effects of
ASP5736 and olanzapine on MAP-induced hyperactivity in mice.
The inhibitory effect of olanzapine exhibited an approximate 3-
fold increase in potency following the co-administration of
ASP5736 (0.003 mg/kg, p.o.) (Figure 6C).3.4.5. Effect of ASP5736 on catalepsy in mice
Existing antipsychotic drugs are known to induce catalepsy in
rodents, with an index of extrapyramidal side effects (EPS).
We therefore evaluated whether ASP5736 induces catalepsy
in mice. ASP5736 did not induce catalepsy up to 3 mg/kg,
p.o. (Figure 7A). In contrast, olanzapine dose-dependently
increased the duration of catalepsy (Figure 7B). Further, thepotency of olanzapine to induce catalepsy was not enhanced
by 0.003 mg/kg (p.o.) of ASP5736, which had improved
memory deﬁcit in mice (Figure 7C).
3.4.6. Effect of ASP5736 on plasma prolactin level in
mice
Existing antipsychotic drugs are known to increase the plasma
prolactin levels in rodents, as well as in humans. We there-
fore evaluated if ASP5736 increases plasma prolactin levels in
mice. ASP5736 did not inﬂuence plasma prolactin level at
doses ranging from 0.001 to 1 mg/kg (p.o.) in mice as shown
in Table 3. In contract, 0.1 mg/kg (p.o.) of risperidone, the
drug which was evaluated as a positive control, signiﬁcantly
increased the plasma prolactin level (Table 3).
4. Discussion
Several other investigators (Grailhe et al., 2001, Francken
et al., 1998, and Hurley et al., 1998) have conﬁrmed that 5-HT
inhibits adenylate cyclase activity and suppresses forskolin-
induced cAMP accumulation by expressing the cloned 5-HT5A
receptor in HEK-293 cells. And Noda et al. (2003) hypothesized
that the activation of 5-HT5A receptor-induced IP3 formation
might in turn cause a transient increase in intracellular Ca2+
concentration. In support of this hypothesis, they reported a
5-HT-induced transient outward current in 5-HT5A receptor-
expressing cells. Therefore, at ﬁrst, we examined the in vitro
proﬁles of our compound ASP5736. The compound antagonized
the 5-CT-induced Ca2+ inﬂux with an IC50 value of 1.02 nM,
being similar potency to its binding afﬁnity to 5-HT5A receptor.
Further, ASP5736 was shown to dose-dependently antagonize
the 5-CT-induced decrease in cAMP in 5-HT5A receptor-
expressing HEK293 cells. ASP5736 exhibits more than 200-
fold selectivity for 5-HT5A receptor over other receptors,
enzymes, channels, and other 5-HT subtypes, with the excep-
tion of human 5-HT2c receptor and 5-HT7 receptor. From these
results, we conﬁrmed that ASP5736 is a novel, selective and
potent 5-HT5A receptor antagonist.
Given the distribution of the 5-HT5A receptor mRNA
(Plassat et al., 1992; Matthes et al., 1993; Erlander et al.,Figure 6 Effect of ASP5736 and olanzapine on MAP-induced
hyperactivity in mice. (A) Effect of ASP5736 on MAP-induced
hyperactivity. Each value indicates mean7SEM (n=12 for each
group). (B) Effect of olanzapine on MAP-induced hyperactivity.
Each value indicates mean7SEM (n=8 for each group). (A and B)
##Po0.01, statistically signiﬁcant compared with control (vehi-
cle- and saline-treated) group (Student's t-test). **Po0.01,
statistically signiﬁcant compared with vehicle-treated group
(Dunnett's multiple comparison test). (C) Effect of olanzapine
in combination with ASP5736 on MAP-induced hyperactivity. We
determined the dose of ASP5736 from the effective dose of MK-
801-Y-maze and nPCP-NORT study. control, saline- and vehicle-
treated; MAP, MAP (1.5 mg/kg)- and vehicle-treated and ASP,
MAP (1.5 mg/kg)- and ASP5736 (0.003 mg/kg)-treated. Each
value represents mean7SEM (n=8 for each group). ##Po0.01,
statistically signiﬁcant compared with control (saline- and
vehicle-treated) group (Student's t-test). *Po0.05, **Po0.01,
statistically signiﬁcant compared with MAP (1.5 mg/kg)-
and ASP5736 (0.003 mg/kg)-treated group (Dunnett's multiple
comparison test).
Figure 7 Effects of olanzapine and ASP5736 on catalepsy in
mice Catalepsy time (s) (Max=120 s) of ASP5736, olanzapine
and the effect of olanzapine with ASP5736 (0.003 mg/kg).
(A) Effect of ASP5736 alone. ASP5736-induced catalepsy was
not noted. (B) Effect of olanzapine alone. (C) Effect of
olanzapine with ASP5736. Each value shows the mean7SEM.
(n=8 for each group). **Po0.01, statistically signiﬁcant com-
pared with vehicle-treated group (Dunnett's multiple compar-
ison test). For the combination of olanzapine and ASP5736, the
dose of ASP5736 was determined from the effective dose of
MK-801-Y-maze and nPCP-NORT study.
Table 3 Plasma prolactin level of ASP5736 in mice
Dose
(mg/kg, p.o.)
Plasama prolactin
(ng/mL)
Vehicle 0 4.3070.83
ASP5736
0.001 3.2170.27
0.01 5.1871.29
0.1 2.8570.29
1 5.2672.06
Risperidone 0.1 33.2373.71**
Plasma prolactin level of ASP5736 (positive control is risper-
idone 0.1 mg/kg at 0.5 h after oral administration) were
measured at 1 h after oral administration of ASP5736 in
mice. All data are expressed as mean7SEM (n=5 for each
group).
nnPo0.01, statistically signiﬁcant compared with vehicle-
treated group (by Dunnett's multiple comparison test).
M. Yamazaki et al.17061993; Pasqualetti et al., 1998; Kinsey et al., 2001) and
protein (Duncan et al., 2000; Oliver, Kinsey, 2000; Wang
et al., 2000) and previous ﬁndings from analysis of 5-HT5A
receptor KO mice (Grailhe et al., 2001), we focused onschizophrenia as the therapeutic target of a selective
5-HT5A receptor antagonist. One of the important ﬁndings
of the present study was that ASP5736, but not olanzapine,
ameliorated acute MK-801-induced working memory deﬁcit
in Y-maze (Marta et al. 2005; Olakunle et al. 2012) and
neonatal-PCP-induced visual learning deﬁcit in NORT, sug-
gesting that ASP5736 could be beneﬁcial for the cognitive
deﬁcits in putative animal models of cognitive deﬁcits of
schizophrenia.
The discovery that noncompetitive NMDA receptor anta-
gonists PCP, MK-801 and ketamine induce psychotic reac-
tions in adult human subjects that resemble schizophrenia
symptoms led to the theory that glutamatergic neuronal
dysfunction is involved in the etiology and pathophysiology
of schizophrenia (Javitt and Zukin 1991). A single treatment
of MK-801 or chronic treatment with PCP in adult rodents
induced cognitive impairment in NORT (Kunitachi et al.
2009). Neonatal treatment with PCP induces an increase in
spontaneous motor activity, impairment of prepulse inhibi-
tion, and behavioral changes with regard to learning and
cognition (Andersen and Pouzet 2004; Depoortere et al.
2005) as well as apoptotic neurodegeneration in adult rats,
symptoms associated with the pathology of schizophrenia
(Wang et al. 2001). The current study conﬁrms that
neonatal treatment with PCP does indeed induce cognitive
impairment in NORT in mice on maturation into adults.
Furthermore, neonatally PCP-treated mice, which had been
treated with PCP on postnatal days 7, 9 and 11, were used in
the NORT at 8–9 weeks old. As PCP does not remain in the
body at the time of NORT, we don't think that the effects
observed with ASP5736 reﬂected mere pharmacological
reversal, at least in this model.
At present, we are examining the mechanism by which
ASP5736 exerts efﬁcacy in various animal models of cognitive
impairment using microdialysis, immunohistochemistry, and
microarray studies. We recently discovered (Yamamoto et. al,
unpublished observation) by immunostaining that 5-HT5A
receptors are co-expressed on DA neurons (TH-positive) in
VTA (ventral tegmental area). We therefore hypothesize that
ASP5736 in VTA might block the inhibitory 5-HT5A receptor on
1707ASP5736, a novel 5-HT5A receptor antagonistDA neurons projecting to the mPFC (medial prefrontal cortex)
and thereby improve cognitive impairment by activating DA
neurons in the mPFC. The results will be published elsewhere
after completing studies.
Add-on studies with olanzapine in our present study have
revealed a number of ﬁndings. Although olanzapine failed to
improve MK-801-induced spontaneous alternation behavior
deﬁcit, ASP5736 with olanzapine signiﬁcantly attenuated
such behavior to the same degree as ASP5736 administered
alone. Further, the sedative effect of olanzapine was not
enhanced by ASP5736 at 0.003 mg/kg, which is an effective
dose against MK-801-induced spontaneous alternation deﬁ-
cit. MAP-induced hyperactivity (positive-like symptom
model) was also found to be signiﬁcantly ameliorated
by ASP5736 alone, and the inhibitory effect on MAP-
induced hyperactivity of olanzapine increased potency by
approximately three-fold following administration of
ASP5736. The catalepsy liability of olanzapine was also not
affected by 0.003 mg/kg of ASP5736, a dosage which
improved memory deﬁcit in mice. Taken together, these
ﬁndings suggest that ASP5736 alone signiﬁcantly amelio-
rated MAP-induced hyperactivity at the same dosage as in
combination with olanzapine, it is possible that it works via
a distinct mechanism from olanzapine. Of note, the adverse
effects (sedation and catalepsy) of olanzapine were not
worsened by the co-administration of ASP5736.
Here, we clearly indicate for the ﬁrst time that ASP5736
is a novel and potent 5-HT5A receptor antagonist that can
improve positive-like symptoms and cognitive impairment in
animal models of schizophrenia without adverse effects. Of
further note, these effects are not reduced on co-
administration with the existing antipsychotic olanzapine,
suggesting that ASP5736 may satisfy current unmet medical
needs for the treatment of schizophrenia and also that the
compound can be treated in combination with existing
antipsychotics like olanzapine.Role of funding source
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